Nicholas Tan retweeted
From study design to funding to career pathways, Clinical Trials Research: Upping Your Game brought together future clinical trial leaders.
Two days of insights, mentorship, & momentum for the future of CV research at Heart House. bit.ly/4uR2cMl
#TheFaceOfCardiology
Nicholas Tan retweeted
Extravascular Implantable Cardioverter Defibrillator Lead Fracture and Challenges with Revision
@nicktanCV
heartrhythmcasereports.com/a…
Nicholas Tan retweeted
Replying to @abhishek_mbbs
Leadless Pacemaker vs. Transvenous Pacemaker in Patients Undergoing Transvenous Lead Removal for Infected Cardiac Implantable Electronic Devices in the United States
@SidAgarwalMBBS @MayoClinicCV
heartrhythmjournal.com/artic…
I showcased our first efforts using “pulsed field defibrillation” for terminating atrial and ventricular fibrillation at #ESC2025 @MayoCVservices @MayoEPFellows @DrDeese99 Links included:
esc365.escardio.org/presenta…
esc365.escardio.org/presenta…
Our take on mechanisms and treatment of atrial fibrillation in cancer. Great job Nate Davis and @prasitlumkum! @MayoClinicCV @MayoMN_IMRES @MayoCVFellows mdpi.com/2077-0383/13/24/775…
Nicholas Tan retweeted
Productive day at #AHA24 proud of the VT ablation research showcased by our team @Pragyatf @DrAasthaPoddar @aksuggie_dr great discussion in AI in electrophysiology led by @JagSinghMD @SumeetSChugh @netta_doc signing off!
@MayoClinicCV – at Chicago, IL
Dr Duy Nguyen from @MayoClinicCV kicking off EP education at #AHA2024
Nicholas Tan retweeted
Atrial fibrillation’s hidden compass: The left atrium and the future o... sciencedirect.com/science/ar… @abhishek_mbbs @nicktanCV
Nicholas Tan retweeted
Atrial Fibrillation’s Hidden Compass: The Left Atrium and the Future of Risk Stratification - Heart Rhythm heartrhythmjournal.com/artic…
Nicholas Tan retweeted
nature.com/articles/s41375-0…
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: anunderrecognized source of major bleeding events
Wonderful work by our phenomenal up and coming Clinician Investigator in WM
@KLChohan
@MayoMyeloma
Glad to have had the chance to listen to Rod Tung speak at Mayo! He’s a role model for many of us in our field. As an Asian in EP, that means a lot to me. Thank you!
Very memorable two days visiting the team at the world famous Mayo Clinic. Thank you for having me @SurajKapa @noseworthypeter @drpaulfriedman @SivaMulpuruMD @konsiont and fellows. The number of cultural notes and impressions that I shall take with me are immeasurable.
6
799
Nicholas Tan retweeted
In advanced #HFpEF, sudden cardiac death occurred in 12.4% at 3 years. #CardioTwitter #Epeeps @nicktanCV @shannonmdunlay
doi.org/10.1161/CIRCEP.123.0…
Nicholas Tan retweeted
Proud of our research team at @MayoClinicCV who presented multiple abstracts from our VT ablation database with detailed intraprocedural characteristics and our translational lab data on the effect of PFA on GP ablation. Stellar work 🙌🏽 @HRSonline @jczerpa @Pachon_CNA – at Boston, MA
Nicholas Tan retweeted
An interesting and somewhat unexpected observation involving our initial experience with mavacamten post-FDA approval from @MCastrichiniMD and team!
Incidence of Newly Recognized Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten
@JohnGiudicessi
heartrhythmjournal.com/artic…
Thanks for giving us the chance to share this!
In a study of 1992 TAVR patients, 15 (0.75%) developed RBBB post-TAVR, of whom 10 (66.7%) needed PPM for high-grade AV block. Post-TAVR RBBB had ↑8.36x PPM risk vs no-RBBB #AHAJournals #Epeeps doi.org/10.1161/CIRCEP.123.0…
3
403
Post-TAVR, though rare, is a strong risk factor for high grade AV block:
ahajournals.org/doi/10.1161/…
Glad to have the chance to report this! @MayoClinicCV @MayoEPFellows @akillumd @SivaMulpuruMD @drpaulfriedman @abhishek_mbbs

































